FDA Evaluates Illumina GA, 454 for Vaccine QC; Looks to Implement Method for Polio Vaccine

"We believe this is an ultimate tool for monitoring the genetic stability of all viral vaccines — not only live, but also inactivated vaccines," Konstantin Chumakov, associate director for research at the FDA's Office of Vaccines Research and Review, told In Sequence.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.